scispace - formally typeset
Search or ask a question

Showing papers by "Pierre Larochelle published in 2007"


Journal ArticleDOI
TL;DR: All hypertensive patients with dyslipidemia should be treated using the thresholds, targets and agents outlined in the Canadian Cardiovascular Society position statement, and selected high-risk patients with hypertension but who do not achieve thresholds for statin therapy according to the position paper should nonetheless receive statin Therapy.

134 citations


Journal ArticleDOI
TL;DR: It is indicated that therapy with amlodipine increases peripheral sympathetic basal tone and reactivity to standing in patients with hypertension, whereas valsartan does not.
Abstract: To compare the effects of valsartan and amlodipine alone or in combination on plasma norepinephrine (NE) at rest and standing for 10 minutes in patients with hypertension, 47 patients with a sitting diastolic blood pressure (BP) (DBP) >95 mm Hg and 90 mm Hg (nonresponders) received combination therapy with the other drug, whereas patients with a DBP <90 mm Hg (responders) continued on monotherapy Decreases in ambulatory BP and clinic systolic BP and DBP were significant (P<05) after 8 weeks' therapy with no difference between the 2 groups Amlodipine but not valsartan as monotherapy consistently increased NE levels at rest and enhanced NE levels during standing Valsartan decreased basal NE in responders Combination therapy with valsartan and amlodipine did not attenuate the rise in NE levels induced by amlodipine This study indicates that therapy with amlodipine increases peripheral sympathetic basal tone and reactivity to standing in patients with hypertension, whereas valsartan does not Combined therapy with amlodipine/valsartan did not attenuate the sympathetic activation induced by amlodipine The hypotensive action of valsartan may be mediated in part by an inhibition of the sympathetic baroreflex in patients with hypertension

32 citations